Effects of long-term cryopreservation on peripheral blood progenitor cells

References

• Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, . Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–5.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA. Multiple myeloma, 2004: one or two transplants?N Engl J Med. 2003;349:2551–3.
   PubMedGoogle Scholar
• Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–8.
   PubMed Web of Science ®Google Scholar
• Spurr EE, Wiggins NE, Marsden KA, Lowenthal RM, Ragg SJ. Cryopreserved human haematopoietic stem cells retain engraftment potential after extended (5–14 years) cryostorage. Cryobiology. 2002;44:210–7.
   PubMedGoogle Scholar
• Donnenberg AD, Koch EK, Griffin DL, Stanczak HM, Kiss JE, Carlos TM, . Viability of cryopreserved BM progenitor cells stored for more than a decade. Cytotherapy. 2002;4:157–63.
   PubMed Web of Science ®Google Scholar
• Ayello J, Semidei-Pomales M, Preti R, Hesdorffer C, Reiss RF. Effects of long-term storage at –90 degrees C of bone marrow and PBPC on cell recovery, viability, and clonogenic potential. J Hematother. 1998;7:385–90.
   PubMedGoogle Scholar
• Kobylka P, Ivanyi P, Breur-Vriesendorp BS. Preservation of immunological and colony-forming capacities of long-term (15 years) cryopreserved cord blood cells. Transplantation. 1998;65:1275–8.
   PubMed Web of Science ®Google Scholar
• Mugishima H, Harada K, Chin M, Suzuki T, Takagi K, Hayakawa S, . Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. Bone Marrow Transplant. 1999;23:395–6.
   PubMedGoogle Scholar
• Rybka WB, Mittermeyer K, Singer JW, Buckner CD, Thomas ED. Viability of human marrow after long-term cryopreservation. Cryobiology. 1980;17:424–8.
   PubMedGoogle Scholar
• Lioznov M, Dellbrugger C, Sputtek A, Fehse B, Kroger N, Zander AR. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant. 2008;42:121–8.
   PubMed Web of Science ®Google Scholar
• Martin-Henao GA, Torrico C, Azqueta C, Amill B, Querol S, Garcia J. Cryopreservation of hematopoietic progenitor cells from apheresis at high cell concentrations does not impair the hematopoietic recovery after transplantation. Transfusion. 2005;45:1917–24.
   PubMedGoogle Scholar
• Akkok CA, Liseth K, Hervig T, Ryningen A, Bruserud O, Ersvaer E. Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators. Cytotherapy. 2009;11: 749–60.
   PubMed Web of Science ®Google Scholar
• Fois E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, . Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant. 2007;40:831–5.
   PubMed Web of Science ®Google Scholar
• Milone G, Mercurio S, Strano A, Leotta S, Pinto V, Battiato K, . Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age. Cytotherapy. 2007;9:348–55.
   PubMed Web of Science ®Google Scholar
• StemCell Technologies. Human Colony-Forming Cell Assays Using MethoCult. Version 3.0 edn. Vancouver, Canada: StemCell Technologies; 2004. p. 1–40.
   Google Scholar
• Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol. 1999;21:301–8.
   PubMedGoogle Scholar
• Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5:55–65.
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–26.
   PubMedGoogle Scholar
• Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant. 2005;36:199–204.
   PubMed Web of Science ®Google Scholar
• Abrahamsen JF, Wentzel-Larsen T, Bruserud O. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2 × 106 CD34+ cells/kg. Cytotherapy. 2004;6:356–62.
   Google Scholar
• Amigo ML, del Canizo MC, Caballero MD, Vazquez L, Corral M, Vidriales B, . Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Bone Marrow Transplant. 1999;24:289–93.
   PubMed Web of Science ®Google Scholar
• Armitage S, Hargreaves R, Samson D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant. 1997;20:587–91.
   PubMed Web of Science ®Google Scholar